deltatrials

Fallopian tube transitional cell carcinoma Trials in Oklahoma City, United States

Conditions / Fallopian tube transitional cell carcinoma / Oklahoma City, United States

Fallopian tube transitional cell carcinoma is a medical condition with active clinical research programs worldwide.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT00108745 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer UNKNOWN PHASE3
NCT00565851 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT00719303 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer UNKNOWN PHASE3
NCT02446600 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ACTIVE_NOT_RECRUITING
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors ACTIVE_NOT_RECRUITING
NCT00262847 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer COMPLETED PHASE3
NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer COMPLETED PHASE3
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors ACTIVE_NOT_RECRUITING
NCT02502266 Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer ACTIVE_NOT_RECRUITING

Related Pages